Skip to the main content
Evora
The library

Cardiovascular · Marker 01

ApoB · Apolipoprotein B

ApoB counts the number of cholesterol-carrying particles in your blood that can build up inside artery walls. Each particle carries one ApoB, so the number is the count.

Educational, never diagnosticReviewed Apr 12, 2026

Common reference range

40–80 mg/dL

Worth watching
Above 100 mg/dL
Population median
95 mg/dL
Units
mg/dL

Your record always keeps the range printed on the report the result came from, which can differ from the range above.

Why it matters

What ApoB tells you.

More particles, more chances for one to lodge in an artery. Two people can have the same cholesterol number and very different particle counts. ApoB tells you which person you are.

Apolipoprotein B is the structural protein wrapped around every atherogenic particle in your circulation. Each particle carries exactly one ApoB. Count the ApoB and you have measured the population of particles capable of depositing in an arterial wall, the actual mechanism of atherosclerosis, not a proxy for it.

For decades the standard lipid panel has reported LDL-C, the cholesterol concentration carried inside LDL particles. It is useful, but two patients with identical LDL-C can carry meaningfully different particle counts and therefore meaningfully different decade-out risk. ApoB resolves the ambiguity in a single measurement.

What the record reads

The direction, not one number.

Your ApoB across years, against your own baseline. Direction matters more than any single reading.

ApoB · mg/dL · six results

Illustrative series

Once you file two results, the record compares them to each other rather than to a population average, and names the report each value came from.

What can influence it

The things that move ApoB.

In rough order of effect, and read alongside your own history rather than on their own.

  1. 01

    Statin or PCSK9 therapy

    The most reliable downward lever. Effect within 6 weeks.

  2. 02

    Saturated fat reduction

    Modest but real. 5, 10 mg/dL achievable through diet alone.

  3. 03

    Body composition

    Visceral fat loss reduces hepatic ApoB output.

  4. 04

    Insulin sensitivity

    Improving HOMA-IR pulls ApoB lower without a separate intervention.

  5. 05

    Lp(a) burden

    An inherited multiplier. Read alongside, never instead.

Daily things that show up here

  • Lower saturated fat in regular meals
  • Improve sleep and reduce visceral fat
  • Take a statin if your doctor prescribes one
  • Move daily; resistance train weekly

In your record

What happens when a ApoB result arrives.

The same four steps for every result, whether you upload a report or type a value in by hand.

  1. 01

    Filed to its date

    The value is stored against the day it was drawn, with the report it came from kept alongside it.

  2. 02

    Named and normalized

    Apolipoprotein B is recognised as one measure, so the same marker from two labs joins one series.

  3. 03

    Read in plain language

    You see what it measures, whether it sits in the printed range, and what usually moves it.

  4. 04

    Shared only if you say so

    A clinician sees this result when you grant scoped, expiring access, and the view is logged.

This page is educational. It does not diagnose, and it does not replace a conversation with a clinician who can see your history.

Where to go next

  • Start with one report

    Upload a single lab report and ApoB is filed to its date, named and read back in plain language.

    Create my free record

  • Find someone to read it with

    The directory opens filtered to clinicians who work with cardiovascular markers.

    Verified clinicians

  • Read the evidence

    The reading list opens searched for ApoB, with every study linked back to its source.

    Studies on ApoB

Read alongside

Other cardiovascular markers.

Further reading

Longer pieces on this marker.

References

Where this comes from.

  1. Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and Cardiovascular Disease. JAMA Cardiol. 2019;4(12):1287-1295. DOI
  2. Marston NA, Giugliano RP, Melloni GEM, et al. Association Between Apolipoprotein B-Containing Lipoproteins and Cardiovascular Events. JAMA Cardiol. 2022;7(3):250-256. DOI
  3. Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111-188. DOI

Reviewed by Dr. Aaron Chen, MD · Cardiology · Last reviewed Apr 12, 2026